Market Intelligence, Clinical Progress, and High-Purity Reagents for IGF Signaling Modulation
Key Mutations and Functional Domains
IGFALS (acid-labile subunit) contains Leucine-Rich Repeat domains (LRRNT and LRRCT) critical for ternary complex formation with IGF-1 and IGFBP-3. Pathogenic mutations associated with ALS deficiency (ACLSD) include single nucleotide variants such as those in dbSNP:rs766004600 and rs35947557, which disrupt complex stability or secretion. Understanding these mutations is essential for designing replacement therapies and structure-activity relationship studies.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IGFALS drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IGFALS Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View IGFALS Products |
| Gene Delivery | IGFALS Promise-ORF / Lentivirus Full-length ORF for stable cell lines and secretion studies. |
View IGFALS Products |
| Benchmark Ab | Anti-IGFALS Reference Antibody Recombinant positive control for ternary complex disruption assays. |
View IGFALS Products |
| Validator | IGFALS siRNA Set For knockdown verification and specificity controls. |
View IGFALS Products |
| Related Target 1 | IGF1R (IGF-1 Receptor) Downstream signaling node; essential for IGF-1/2 bioactivity analysis. |
View IGF1R Products |
| Related Target 2 | IGFBP3 Essential ternary complex binding partner; stability regulation. |
View IGFBP3 Products |
| Related Target 3 | IGF1 Ligand required for ternary complex assembly assays. |
View IGF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex Assembly (IGF-1/IGFBP-3/ALS) | Trio combination proteins available; Sequence Verified; Endotoxin <1EU/ug for sensitive cell assays; Native glycosylation preserved (HEK293 expression) |
| Acid Lability Conformational Testing | pH-stabilized buffer formulations; High-purity monomeric protein (>95% by SEC-HPLC); Theoretical MW verified by Mass Spec |
| Cross-species Cyno/Mouse/Human Evaluation | Ortholog proteins available with >95% purity; Species-specific glycosylation patterns preserved |
| Off-target Binding (IGFBP-5 vs IGFBP-3 selectivity) & Epitope Mapping | Homolog panel proteins strictly verified by mass spec; domain deletion mutants available for binding site mapping; Sequence Verified |
| False Positives / Specificity Controls | Validated siRNA included for knockdown verification; Anti-IGFALS reference antibody as blocking control; Endotoxin controlled (<1EU/ug) |
Live IGFALS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IGFALS-targeted therapeutics is intensifying, with major players shifting focus from direct IGF-1R inhibition to upstream complex modulation. As first-generation IGF-1R inhibitors face resistance mechanisms, the next wave of R&D targets the acid-labile subunit to indirectly regulate IGF-1/2 bioavailability without complete pathway ablation. The therapeutic duality of IGFALS—both as an inhibition target for oncology (disrupting IGF stability) and as a replacement therapy for ALS deficiency (monogenic short stature)—drives bifurcated assay requirements for binding disruption versus complex stabilization. Recombinant protein replacement (rhALS) aims to restore the 150 kDa ternary complex and extend IGF-1 half-life, while monoclonal antibodies seek to destabilize circulating complexes in solid tumors. Precision epitope engineering and high-concentration subcutaneous formulations are emerging priorities to avoid off-target interactions with related leucine-rich repeat proteins and to improve patient compliance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Anti-ALS) | Novartis, Oncology Innovators | Solid Tumors (IGF signaling inhibition) | Ternary Complex Disruption Assay (Need high-purity native glycosylated ALS) |
| Recombinant Protein Therapy | Endocrine Biotechs, Rare Disease Biotechs | ALS Deficiency, Growth Failure | Complex Stability Assay (Need WT vs Mutant ALS proteins) |
| Small Molecule (PPI Disruptor) | Academic Consortia | Metabolic Disorders | SPR/BLI Binding Assay (Need acid-labile conformation) |
| Bispecific (ALS/Albumin) | Emerging Platforms | Half-life Extension | Heterodimer Validation (Need Cross-reactive Abs) |
| Gene Therapy | Rare Disease Gene Therapy Platforms | Monogenic ALS Deficiency | Cell-line Construction (Need Lentiviral ORF particles) |